Inhibitex to Present at the 11th Annual BIO CEO & Investor Conference
February 04 2009 - 11:45AM
Business Wire
Inhibitex, Inc. (Nasdaq: INHX) announced today that it will
present at the BIO CEO & Investor Conference on Tuesday,
February 10, 2009 at 1:45 p.m. EST from the Waldorf=Astoria Hotel
in New York, NY. Russell H. Plumb, president and chief executive
officer of Inhibitex, Inc., and Joseph M. Patti, Ph.D., senior vice
president of research and development and chief scientific officer,
will provide an update on the Company.
A live audio webcast of the presentation will be available in
the �News and Events� section of the Company�s website at
www.inhibitex.com. The webcast will be archived and available on
the Inhibitex website after the event for a period of 30 days.
About Inhibitex
Inhibitex, Inc., headquartered in Alpharetta, Georgia, is a
biopharmaceutical company focused on developing products to treat
and prevent serious infectious diseases. The Company�s pipeline
includes FV-100, its clinical-stage oral nucleoside analogue in
development for the treatment of herpes zoster (shingles), as well
as a series of HCV nucleoside polymerase inhibitors and HIV
integrase inhibitors. Inhibitex has also licensed certain of its
proprietary MSCRAMM� protein technology to Wyeth for the
development of staphylococcal vaccines and to 3M for the
development of diagnostics.
For additional information about the Company, please visit
www.inhibitex.com.
Inhibitex� and MSCRAMM� are registered trademarks of Inhibitex,
Inc.
Inhibitex, Inc. (MM) (NASDAQ:INHX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Inhibitex, Inc. (MM) (NASDAQ:INHX)
Historical Stock Chart
From Jul 2023 to Jul 2024